Lumida
/VKTX
⌘K
Viking Therapeutics Inc

Viking Therapeutics Inc

VKTX
$37.08USD↑+1.95%+0.71 today

MARKET CAP

4.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$35 – $38

52W RANGE

$23
$43

AI Summary

Stalk
StalkMedium

VKTX is in a Stage 2 acceleration phase, marked by a parabolic rally but facing extreme overbought and exhaustion signals. The medium-term bias remains bullish given the continuation pattern and rising moving averages, yet short-term timing is unfavorable. We recommend stalking pullbacks into the rising EMAs or prior breakout zone for a more favorable entry.

  • ↑Initiated Phase 1 trial for VK3019 dual amylin/calcitonin obesity therapy.
  • ↑Stock up 17.5% in 7 days and 43.6% over past year.
  • ↓Negative earnings yield and poor profitability metrics suggest overvaluation risk.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Viking Therapeutics, Inc. (NASDAQ: VKTX) is a biotech company that is primarily focused on developing innovative therapies for metabolic and endocrine disorders. Recently, it has made strides in the obesity treatment market with its investigational dual amylin and calcitonin receptor agonist (DACRA), VK3019. Viking is well-positioned within the weight loss therapeutic landscape, potentially benefiting from the ongoing obesity epidemic, and is competing against established players like Eli Lilly and Novo Nordisk, especially in the GLP-1 and GIP drug market.

Bull says

  • ↑Initiated Phase 1 trial for VK3019 dual amylin/calcitonin obesity therapy.
  • ↑Stock up 17.5% in 7 days and 43.6% over past year.
  • ↑High institutional ownership underscores strong investor backing.
  • ↑Dual-action mechanism may differentiate VK3019 from GLP-1 rivals.
  • ↑Low interest-rate sensitivity offers stability amid macro shifts.
  • ↑Obesity market projected to hit $100 bn, large addressable market.

Bear says

  • ↓Negative earnings yield and poor profitability metrics suggest overvaluation risk.
  • ↓High leverage risk and low liquidity could strain trial funding.
  • ↓Elevated short interest reflects market skepticism on near-term prospects.
  • ↓High volatility implies potential for sharp price swings.
  • ↓Oversaturated weight-loss market from Eli Lilly and Novo Nordisk intensifies competition.
  • ↓P/B ratio above peers highlights potential overvaluation concerns.

Investment themes with VKTX

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT
Weight Loss↓ -0.82%

Products and services targeting weight management

LLY · NVO · PFE

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 07-05-2026bullish

Transcript signals

Bull points

  • 2025 marked a strong year of execution. We generated over $1 billion of pretax adjusted operating earnings, $168 million higher than a year ago. And we increased earnings per share 22% to $8.85. This included EPS of $1.94 in the quarter, which was up 39% from last year. These results were driven by management action throughout the year as we delivered above-plan financial results across all our strategic priorities.
  • We generated a record $28 billion of organic defined contribution net inflows in 2025, and we added $60 billion of assets from OneAmerica. Together, this supported a 30% increase in total defined contribution assets to approximately $730 billion at year-end. We now have a base of approximately 10 million participant accounts for us to serve both to and through retirement.
  • Adjusted operating earnings were $152 million in the full year, significantly improved from $40 million in the prior year. A key driver of this improvement included Stop Loss, which I will discuss in a moment.

Bear points

  • Claims experience on the '25 book is developing modestly better than the prior year. However, ensuring we have a well-supported reserve level heading into first quarter is essential.
Read full transcript analysis ›